Enbrel News and Research

RSS
Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Hanwha, Merck partner to develop and commercialize HD203

Hanwha, Merck partner to develop and commercialize HD203

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reports $3,816 million for 2010 third quarter revenue

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Abbott's Humira gains first-line biologic use for psoriasis treatment: Report

Abbott's Humira gains first-line biologic use for psoriasis treatment: Report

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

Amgen second-quarter total revenue increases 2% to $3,804 million

Amgen second-quarter total revenue increases 2% to $3,804 million

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

BioTrends reports increase in usage of Actemra for RA

BioTrends reports increase in usage of Actemra for RA

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion